In a major stride toward tackling aggressive breast cancer, researchers from The Hebrew University of Jerusalem have developed druglike molecules that degrade a previously “undruggable” cancer-driving protein. The target, HuR—an RNA-binding protein known for stabilizing oncogenic messages—has long eluded traditional therapies. Now, using next-generation strategies involving molecular glues and PROTACs, researchers have uncovered a promising route to disarm HuR and suppress tumor growth from the inside out.
Airovation Technologies was awarded the prestigious 2025 Asper Prize for “The Hebrew University Rising Startup”. The prize, part of a competition launched by ASPER-HUJI Innovate, the university’s Center for Innovation and Entrepreneurship in collaboration with the Asper Foundation, drew entries from more than fifty startups. Airovation Technologies secured the top spot after presenting to an international panel of judges.
